Dr Reddy#39;s drops 4% after being named in US anti-trust lawsuit
The complaint accuses Dr Reddy#39;s of improperly restraining competition and maintaining a monopoly in the sale of the cancer drug Revlimid
Read MoreThe complaint accuses Dr Reddy#39;s of improperly restraining competition and maintaining a monopoly in the sale of the cancer drug Revlimid
Read MoreFund managers believe that the regulatory advisory on smallcap funds will not have an impact on the broader markets but will improve transparency in the mutual fund space. However, they suggest that investors be cautious in this space as valuations…
Read MoreIndian generic companies have benefited from the continuing shortages and approval slowdown in the US.
Read MoreFor the market to move higher, banking names have to participate in the rally, say experts
Read MoreIn the villa project, the company will offer 56 villas while the other project will offer 144 luxury apartments.
Read MoreGeojit is bullish on Manappuram Finance has recommended buy rating on the stock with a target price of Rs 215 in its research report dated March 01, 2024.
Read More